28日投资提示：金23转债不下修

Group 1 - The core viewpoint of the article highlights the approval of a product by a subsidiary of Jianyou Co., Ltd. from the FDA, which is a significant milestone for the company [1][2]. - The article mentions that the Jin 23 convertible bond will not undergo any adjustments, indicating stability in its terms [2]. - The article provides a detailed table of various convertible bonds, including their current prices, redemption prices, last trading dates, and conversion values, which are essential for investors to assess their investment options [4][6]. Group 2 - Jianyou Co., Ltd.'s subsidiary has received FDA approval for its injectable product, Daba Wanxing, which could enhance the company's market position and growth potential [1]. - The article lists several convertible bonds with their respective financial metrics, such as the current price of 110.499 for Hengbang Convertible Bond and a conversion value of 110.63, which reflects the bond's performance [4]. - The convertible bond market is highlighted with various bonds showing different metrics, such as the Z Qibin Convertible Bond with a current price of 109.529 and a conversion value of 109.95, indicating the diverse investment opportunities available [4][6].